MM28Homo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 1 publications

Quick Overview

Cell line for uveal melanoma research with mTOR pathway activation.

Detailed Summary

MM28 is a cell line derived from uveal melanoma, established to study the genetic and molecular characteristics of this aggressive ocular cancer. It exhibits activation of the mTOR signaling pathway, which is implicated in cell proliferation and survival. Research on MM28 has focused on evaluating the efficacy of mTOR inhibitors like Everolimus, demonstrating significant effects on cell viability and tumor growth in preclinical models. The cell line is part of a panel of UM cell lines that recapitulate the genetic landscape of uveal melanoma, providing a valuable tool for drug development and therapeutic strategy testing.

Research Applications

Uveal melanoma researchmTOR pathway studiesDrug efficacy testing

Key Characteristics

Activation of mTOR pathwaySensitivity to EverolimusGenetic alterations consistent with uveal melanoma
Generated on 6/21/2025

Basic Information

Database IDCVCL_4D15
SpeciesHomo sapiens (Human)
Tissue SourceLiver[UBERON:UBERON_0002107]

Donor Information

Age72
Age CategoryAdult
SexMale

Disease Information

DiseaseUveal melanoma
LineageEye
SubtypeUveal Melanoma
OncoTree CodeUM

DepMap Information

Source TypeATCC
Source IDACH-002013_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleGNA11p.Gln209Leu (c.626A>T)Unspecified-PubMed=22236444
MutationSimpleBAP1p.Tyr627Ter (c.1881C>A)Unspecified-PubMed=24994677

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11
D13S317
8,11
D16S539
10,12
D21S11
28,29
D5S818
11
D7S820
8,10
TH01
7,9.3
TPOX
11
vWA
17,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Roman-Roman S.

Mol. Oncol. 8:1508-1520(2014).